Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Eda Eylemer Mocan, Medical oncologist at Ankara university, shared a recent article by Daniel P. Petrylak on X:

“TROPHY-U-01 Cohort 2
SG in Metastatic Urothelial Cancer

• Cisplatin-Ineligible
• Progressing after ICI

• Med f/u 9.3 m, ORR 32%, DOR 5.6 m
• Grade ≥3 AE 87% of pts
• Neutropenia 34%
• Anemia 24%
• Fatigue 18%
• Diarrhea 16%

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Authors: Daniel P. Petrylak, MD, Scott T. Tagawa, MD, Rohit K. Jain, MD, Manojkumar Bupathi, MD, Arjun Balar, MD,Arash Rezazadeh Kalebasty, MD, Saby George, MD and Petros Grivas, MD, PhD

Source: Eda Eylmer Mocan/X